Since 1983, Townsend Letter has been publishing
a print alternative medicine magazine. As a forum for the entire
alternative medicine community, we present scientific information
on a wide variety of alternative medicine topics —including
EDTA Chelation Therapy.
OCTOBER 11-13: 27TH ANNUAL IAACN SCIENTIFIC SYMPOSIUM – Infectious Disease: The Influence of Clinical Nutrition on Outcome in Plano, Texas. CONTACT: https://www.iaacn.org/2018-symposium/
National University of Natural Medicine Commencement 2017 to Honor Editor, Herbal Pioneer, Top Students June 2017
This year's National University of Natural Medicine commencement ceremony featured honorary degrees for two natural medicine warriors, Townsend Letter editor and noted physician Jonathan Collin, and pioneering herbalist Rosemary Gladstar.
Jonathan Collin, MD
Dr. Collin received an honorary Doctor of Letters degree in recognition of his work as founder, publisher and editor-in-chief of the Townsend Letter, one of the leading magazines covering complementary and alternative medicine. He is also widely known for his expertise in chelation therapy, used to treat toxic metals poisoning. Read more...
Kirkland physician Dr. Jonathan Collin and his wife, Deborah Nissen-Collin.
Local physician receives two awards from Emord and Associates September 15, 2014
Kirkland physician and editor and publisher of the Townsend Letter was presented with two awards from Emord and Associates. Dr. Jonathan Collin received the Excellence in Integrative Medicine award and the Excellence in Medical Journalism award during the Sacred Fire of Liberty Gala Sept. 5-6 in Cambridge, Maryland. Read story here...
Watch the video below.
Dr. Jonathan Collin's acceptance speech for his Excellence in Integrative Medicine and Excellence in Medical Journalism awards. (Note: Volume is very low. It's not your computer.)
NIH Trial Gives Surprising Boost To Chelation Therapy(Offsite link) With a result that is likely to surprise and baffle much of the mainstream medical community,
a large NIH-sponsored trial has turned up the first substantial evidence in support of
chelation therapy for patients with coronary disease.